Could We One Day Rejuvenate the Optic Nerve? A New Frontier in Glaucoma Research
What if damaged optic nerve cells could be rejuvenated?
One of the biggest challenges in treating glaucoma is that once retinal ganglion cells are significantly damaged, they generally do not regenerate. These specialized nerve cells carry visual information from the retina to the brain through the optic nerve.
Current glaucoma treatments focus primarily on lowering eye pressure to slow or prevent further damage. But what if scientists could go one step further and actually restore some of the function of aging or injured nerve cells?
That is the exciting question behind a new experimental treatment called ER-100.
What exactly is ER-100?
ER-100 is an experimental therapy developed by biotechnology company Life Biosciences. Rather than simply trying to protect nerve cells from additional damage, researchers are investigating whether they can encourage these cells to return to a healthier, more youthful state.
The approach involves something called epigenetic reprogramming.
Think of your DNA as the instruction manual inside every cell. As we age, changes occur in how those instructions are read and used. These changes can affect how well cells function, even though the underlying DNA itself has not changed.
ER-100 is designed to reset some of these cellular instructions.
How does the treatment work?
-
OCT4
-
SOX2
-
KLF4
Together, they are called OSK.
Researchers use a specially modified, harmless delivery virus to introduce the instructions for these three factors into cells in the eye.
The treatment involves:
-
An injection into the eye: ER-100 is administered through a single injection into the vitreous, the gel-like substance inside the eye.
-
An oral medication: Participants also take doxycycline, an antibiotic, for eight weeks. In this experimental approach, doxycycline helps switch on the cellular reprogramming instructions delivered by ER-100.
The goal is to restore healthier cellular activity without completely resetting the cells or changing their identity.
What have the first human studies shown?
Here is where things become particularly interesting.
In October 2026, Life Biosciences announced preliminary findings from the first three human participants with open-angle glaucoma who received the lowest dose of ER-100.
The company reported:
-
All three participants tolerated the treatment through the first 56 days.
-
No serious adverse events were reported during that initial observation period.
-
Two of the three participants showed preliminary improvements in portions of their visual field tests.
A visual field test measures how well a person detects objects or points of light throughout their field of vision.
These early observations are encouraging, but it is important to understand that three patients are far too few to establish whether the treatment actually restores vision or works reliably.
The trial is still in its early stages and is primarily designed to evaluate safety.
Is ER-100 being developed for glaucoma alone?
No. The clinical program is also investigating another optic nerve condition called non-arteritic anterior ischemic optic neuropathy (NAION), which occurs when blood flow to the optic nerve is disrupted.
Both conditions can result in damage to retinal ganglion cells, making them potential targets for this new approach.
Could this technology eventually help other parts of the body?
That is perhaps the most exciting long-term possibility.
Scientists are investigating whether epigenetic reprogramming could eventually have applications beyond the eye, including other aging tissues and organs.
However, ER-100 is currently an eye-directed experimental therapy. It is not an approved whole-body rejuvenation treatment.
What does the future hold?
We are accustomed to thinking of glaucoma treatment as an effort to slow the loss of vision. ER-100 introduces a different possibility: rather than simply protecting remaining nerve cells, perhaps we can eventually restore some of their lost function.
We are not there yet. But the concept represents a potentially important shift in how scientists approach neurodegenerative eye disease.
The ultimate question is no longer just how to protect the optic nerve from further damage, but whether we might someday be able to rejuvenate the nerve cells themselves.
That is a development worth watching!
Clinical note: ER-100 remains investigational and is not an FDA-approved treatment. It should not replace established glaucoma or NAION management.
Further reading: ER-100 Clinical Trial – ClinicalTrials.gov (NCT07290244)
You Might Also Enjoy...
Mouth Breathing
ALS(Amyotrophic Lateral Sclerosis)
Common Hormones and Their Nicknames
EYES are a WINDOW to the KIDNEYS
